Leveraging our deep experience, knowledge, and expertise from three decades of viral vector development and manufacturing, our VirusExpress® lentivirus platform delivers a high performance, high quality solution to de-risk lentivirus production.
Using our VirusExpress® lentivirus platform, our technical experts can accelerate your path to clinical and commercial GMP manufacturing by providing streamlined development, scalable manufacturing, and comprehensive analytics.
Providing high titer, high yield, and high quality products, our VirusExpress® lentivirus platform has been successfully used in numerous clinical programs.
Partnering with us you gain an efficient and knowledgeable approach, and confidence in the quality of the clinical and commercial manufacturing of your lentiviral vector.
Our lentivirus platform is fully comprehensive and tailored to meet your timelines:
Our team of development and manufacturing experts have successfully compressed project timelines and seamlessly scaled-up lentivirus cell and gene therapy programs through IND-submission and into clinical trials.
Trusted to advance lentiviral cell and gene therapies for three decades, we have the expertise and knowhow to support your therapeutic from preclinical development through commercialization.
Contact us to discover how our lentivirus platform can de-risk and optimize your lentiviral vector program to improve performance, quality, reduce costs, and compress development to GMP manufacturing in less than 12 months.
Hear from our viral vector experts as they showcase our capabilities and solutions for cell and gene therapy production and highlight key features of our technologies and GMP facility.
In this webinar, our innovation scientists explore how they optimized our VirusExpress® platform for lentiviral vectors to maximize titer, while providing a streamlined platform to accelerate development timelines to clinical trials.
Discover how partnering experienced viral vector CTDMO can help guide you through the complexities of manufacturing and overcome regulatory hurdles to bring new therapies to patients.
Learn how our Manufacturability Assessment can help identify and address development and manufacturing challenges when bringing new therapies to market.
Watch the video and read the poster to learn how we optimized our VirusExpress® platform for lentiviral vectors to maximize titers, enrich recovery, and reduce time to GMP manufacturing.
In this white paper, we outline how DoE studies were used to define and optimize upstream and downstream workflows, establishing the VirusExpress® LV platform as a high quality and performance solution for suspension-based LV vector manufacturing.
To continue reading please sign in or create an account.
Don't Have An Account?